Euglycemic Protocol for Non-Diabetic Postoperative Patients on Subcutaneous Insulin
For non-diabetic patients requiring subcutaneous insulin postoperatively, initiate a basal-bolus regimen at 0.5-1 IU/kg total daily dose (split 50% basal long-acting insulin and 50% rapid-acting insulin with meals), targeting blood glucose 100-180 mg/dL. 1
Initial Dosing Strategy
When transitioning from IV insulin infusion (if used <24 hours) in patients not previously on insulin with persistent postoperative hyperglycemia:
- Total daily dose: 0.5-1 IU/kg based on patient weight
- Distribution:
- 50% as long-acting basal insulin (glargine or detemir)
- 50% as ultra-rapid acting analog (lispro, aspart) divided before meals
- Meal adjustment: Give only half the anticipated rapid-acting dose if the meal is light 1
Transition from IV Insulin Protocol
If the patient was on continuous IV insulin infusion:
- Maintain IV insulin until blood glucose is stable ≤180 mg/dL (10 mmol/L) 1
- Stop IV insulin when hourly rate is ≤0.5 IU/h at resumption of oral feeding
- Leave IV access in place if rate is ≥5 IU/h (indicates major insulin resistance) 1
- Administer basal insulin immediately after stopping IV insulin—optimal timing is 20:00 hours 1
- Give first rapid-acting dose at the first meal, adjusted to carbohydrate content 1
Target Blood Glucose Range
Maintain blood glucose 100-180 mg/dL (5.6-10.0 mmol/L) in the perioperative period 2, 3. Stricter targets (80-180 mg/dL) do not improve outcomes and increase hypoglycemia risk 2, 3.
Monitoring Requirements
- Check blood glucose every 2-4 hours while NPO 2, 3
- Continue monitoring postoperatively to detect both hyper- and hypoglycemia 1
- Scale up monitoring frequency in patients receiving insulin due to hypoglycemia unawareness 1
Hypoglycemia Management
Immediate treatment required for:
- Blood glucose <60 mg/dL (3.3 mmol/L)—treat immediately even without symptoms 1
- Blood glucose 60-100 mg/dL (3.3-5.5 mmol/L) with symptoms—treat if patient reports hypoglycemia 1
Treatment approach:
- Conscious patients: Oral glucose preferred 1
- Unconscious/unable to swallow: IV glucose immediately, then oral when consciousness returns 1
Hyperglycemia Management
For blood glucose >300 mg/dL (16.5 mmol/L):
- Add ultra-rapid insulin analog
- Ensure adequate hydration
- Do not assume diabetic ketoacidosis in non-diabetics, but monitor closely 1
Critical Distinctions from Diabetic Patients
The key difference for non-diabetic patients is that stress hyperglycemia may resolve as surgical stress subsides. Therefore:
- Reassess insulin needs daily based on blood glucose trends
- Consider discontinuing insulin if all blood glucose values remain <140 mg/dL for 24-48 hours without insulin 4
- Do not automatically discharge patients on insulin—many non-diabetics can discontinue therapy once stress resolves
Common Pitfalls to Avoid
Sliding scale insulin alone: Never use correction-dose-only insulin without basal coverage—this significantly increases complications 1, 2, 3, 4
Premature IV insulin discontinuation: Always administer subcutaneous basal insulin 1-2 hours before stopping IV insulin to prevent rebound hyperglycemia 2, 3, 4
Over-aggressive targets: Targeting <100 mg/dL increases hypoglycemia without improving outcomes 2, 3
Ignoring NPO status: Patients who are NPO still require basal insulin but should not receive prandial insulin 4
Inadequate monitoring: Blood glucose checks every 2-4 hours minimum are essential for safe insulin titration 2, 3